Novo Nordisk A/S lowered its financial forecast in a surprise update that cited lagging sales of its weight-loss drug Wegovy, as the company fights to regain its leading position in the obesity market ...

Novo Nordisk A/S promoted its head of international operations to become its new chief executive officer after a profit ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will need to show more robust growth in the months ahead to bolster market ...

Researchers have discovered a new way to successfully collect amniotic fluid and stem cells directly during vaginal deliveries. Plus, Rush University System for Health is offering an innovative blood ...

CVS acknowledged that Zepbound has been shown to help people lose more weight than Wegovy, but that Wegovy can still help ...

Novo Nordisk’s weight loss drug, Wegovy, is experiencing a surge in new prescriptions following a US ban on its copycat ...

For many years now, the price of insulin has continued to increase, which comes at a cost for those with diabetes who truly ...

UBS Group just sliced their target for CVS Health from $71.00 to $67.00, maintaining a 'neutral' stance. Despite this cut, ...

A lawsuit filed in federal court on behalf of the University of Pennsylvania and its health system alleges that 20 years of skyrocketing prices on drugs that treat diabetes, like insulin, can be ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...